BioLife Solutions (NASDAQ:BLFS) Receives New Coverage from Analysts at HC Wainwright

HC Wainwright initiated coverage on shares of BioLife Solutions (NASDAQ:BLFS) in a research report sent to investors on Monday morning, Marketbeat reports. The brokerage issued a buy rating and a $29.00 target price on the medical equipment provider’s stock.

Other equities research analysts also recently issued research reports about the stock. Craig Hallum upped their price target on shares of BioLife Solutions from $23.00 to $30.00 and gave the company a buy rating in a research note on Monday, August 12th. Northland Securities raised their price target on shares of BioLife Solutions from $26.00 to $28.00 and gave the stock an outperform rating in a research note on Friday, August 9th. Finally, TD Cowen raised their target price on shares of BioLife Solutions from $20.00 to $26.00 and gave the company a buy rating in a research report on Wednesday, July 17th. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of Moderate Buy and a consensus target price of $26.67.

BioLife Solutions Trading Up 2.9 %

Shares of NASDAQ BLFS opened at $25.04 on Monday. BioLife Solutions has a 1 year low of $8.92 and a 1 year high of $26.73. The stock has a market cap of $1.15 billion, a P/E ratio of -17.63 and a beta of 1.87. The firm has a 50-day moving average of $24.51 and a 200 day moving average of $21.28. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.86 and a quick ratio of 1.81.

BioLife Solutions (NASDAQ:BLFS) last announced its quarterly earnings results on Thursday, August 8th. The medical equipment provider reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.08. The firm had revenue of $28.33 million during the quarter, compared to analyst estimates of $23.80 million. BioLife Solutions had a negative net margin of 59.88% and a negative return on equity of 10.75%. As a group, sell-side analysts expect that BioLife Solutions will post -0.36 EPS for the current fiscal year.

Insider Transactions at BioLife Solutions

In other news, EVP Aby J. Mathew sold 10,000 shares of the business’s stock in a transaction dated Wednesday, September 18th. The shares were sold at an average price of $23.90, for a total transaction of $239,000.00. Following the transaction, the executive vice president now owns 317,716 shares of the company’s stock, valued at approximately $7,593,412.40. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, EVP Aby J. Mathew sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $23.90, for a total transaction of $239,000.00. Following the sale, the executive vice president now directly owns 317,716 shares in the company, valued at $7,593,412.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CRO Garrie Richardson sold 3,070 shares of the stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $25.12, for a total transaction of $77,118.40. Following the completion of the transaction, the executive now owns 114,773 shares in the company, valued at $2,883,097.76. The disclosure for this sale can be found here. Insiders sold 16,944 shares of company stock valued at $405,619 over the last 90 days. 2.20% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On BioLife Solutions

Hedge funds and other institutional investors have recently bought and sold shares of the business. 1620 Investment Advisors Inc. acquired a new stake in BioLife Solutions in the second quarter valued at $35,000. Isthmus Partners LLC lifted its stake in shares of BioLife Solutions by 34.4% in the 2nd quarter. Isthmus Partners LLC now owns 165,247 shares of the medical equipment provider’s stock valued at $35,000 after purchasing an additional 42,265 shares in the last quarter. Register Financial Advisors LLC acquired a new position in BioLife Solutions during the 1st quarter worth approximately $96,000. Canada Pension Plan Investment Board acquired a new position in BioLife Solutions during the 2nd quarter worth approximately $122,000. Finally, Arizona State Retirement System acquired a new position in BioLife Solutions during the 2nd quarter worth approximately $217,000. Institutional investors and hedge funds own 93.24% of the company’s stock.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.